v3.26.1
Goodwill and Intangible Assets
 6 Months Ended
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill
Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter or upon the identification of triggering events that would more likely than not reduce the fair value of goodwill below its carrying amount.
On June 30, 2026, the Company completed the sale of its lab products business (see Note 1 to these financial statements). In accordance with ASC 350-20, the Company allocated $4.4 million of goodwill to the divested business based on the relative fair values of the business disposed of and the portion of the reporting unit retained. This amount was derecognized upon closing and included in the net assets sold in determining the gain on sale of lab products business. The Company evaluated the goodwill balance in the retained reporting unit for impairment indicators and no impairment was identified.
The following table presents changes in the carrying amount of goodwill for the six months ended June 30, 2026 (in thousands):

Goodwill
Balance as of December 31, 2025$40,336 
Goodwill derecognized upon sale of lab products business(4,368)
Balance as of June 30, 2026$35,968 
Intangible Assets
The following table presents details of the Company’s intangible assets as of June 30, 2026 (in thousands):
June 30, 2026
Gross Carrying AmountAccumulated AmortizationForeign Currency TranslationNet Carrying AmountWeighted Average Remaining Useful Life
(In Years)
Intangible assets with finite lives:
Acquired and developed technology$7,385 $(4,866)$— $2,519 4.7
Customer relationships12,551 (5,329)— 7,222 7.6
Commercialization rights11,579 (7,654)— 3,925 3.1
Trademarks and tradenames2,600 (1,203)— 1,397 6.9
Total intangible assets with finite lives34,115 (19,052)— 15,063 
Intangible assets with indefinite lives:
Acquired in-process technology1,250 — — 1,250 
Favorable license agreement
2,243 — — 2,243 
Total intangible assets with indefinite lives
3,493 — — 3,493 
Total intangible assets$37,608 $(19,052)$— $18,556 
The following table presents details of the Company’s intangible assets as of December 31, 2025 (in thousands):
December 31, 2025
Gross Carrying AmountAccumulated AmortizationForeign Currency TranslationNet Carrying AmountWeighted Average Remaining Useful Life
(In Years)
Intangible assets with finite lives:
Acquired and developed technology$36,517 $(24,127)$(2,203)$10,187 5.8
Customer relationships25,581 (12,413)(1,639)11,529 7.1
Commercialization rights11,579 (7,022)— 4,557 3.6
Trademarks and tradenames4,860 (2,434)(232)2,194 6.6
Total intangible assets with finite lives78,537 (45,996)(4,074)28,467 
Intangible assets with indefinite lives:
Acquired in-process technology1,250 — — 1,250 
Favorable license agreement
2,243 — — 2,243 
Total intangible assets with indefinite lives
3,493 — — 3,493 
Total intangible assets$82,030 $(45,996)$(4,074)$31,960 
In connection with the sale of the lab products business completed on June 30, 2026 (see Note 1 to these financial statements), the Company derecognized intangible assets, consisting primarily of acquired and developed technology, customer relationships and trademarks. These assets were included in the net assets sold in determining the gain on sale of lab products business. Estimated future amortization expense presented below reflects only intangible assets retained by the Company.
As of June 30, 2026, the Company did not identify any impairment indicators suggesting that the carrying value of the intangible assets was not recoverable.
The following table summarizes the Company’s amortization expense of finite-lived intangible assets (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Cost of testing services$202 $346 $513 $693 
Cost of product— 442 512 854 
Cost of patient and digital solutions153 153 305 305 
Sales and marketing
174 648 817 1,276 
Total$529 $1,589 $2,147 $3,128 
The following table summarizes the Company’s estimated future amortization expense of intangible assets with finite lives as of June 30, 2026 (in thousands):
Years Ending December 31,Total
Remainder of 2026$1,577 
20273,143 
20283,143 
20292,428 
20301,444 
Thereafter3,328 
Total future amortization expense$15,063